睿知中国医院研究地图
候选清单

烟台青岛大学

烟台毓璜顶医院

Yantai Yuhuangding Hospital

在本站收录的 61 种疾病中,这家医院列在其中 24 种下,依据是它牵头的研究论文,以及它作为牵头方或研究中心登记的试验。

这里展示的是公开记录中的研究活动,不是医疗水平评级。能否为某位患者提供帮助,应由医院和主治医生判断。

这家医院的官网还没有核对。

联系这家医院

烟台毓璜顶医院的研究

选择一种疾病,查看背后的论文和试验。 每个方块显示 2021–2025 年牵头的论文数和每年的数量。

只包括本站收录的 61 种疾病。未列出某种疾病,表示在这些记录中这家医院没有达到该病的列出标准,不代表它不诊治该病。 哪些医院会被列出

  1. 鼻咽癌Nasopharyngeal carcinoma3 篇牵头论文
  2. 肝细胞癌Hepatocellular carcinoma12 篇牵头论文
  3. 胃癌Stomach cancer33 篇牵头论文
  4. 肺癌Lung cancer47 篇牵头论文牵头 1 项开放试验
  5. 胰腺癌Pancreatic cancer7 篇牵头论文
  6. 乳腺癌Breast cancer45 篇牵头论文牵头 1 项开放试验
  7. 视网膜母细胞瘤Retinoblastoma2 篇牵头论文
  8. 骨肉瘤Osteosarcoma3 篇牵头论文
  9. 胃肠道间质瘤Gastrointestinal stromal tumour2 篇牵头论文
  10. 神经母细胞瘤Neuroblastoma1 篇牵头论文
  11. 再生障碍性贫血Aplastic anaemia1 篇牵头论文
  12. 噬血细胞性淋巴组织细胞增生症Haemophagocytic lymphohistiocytosis1 篇牵头论文
  13. 淋巴瘤Lymphoma12 篇牵头论文
  14. 血栓性血小板减少性紫癜Thrombotic thrombocytopenic purpura1 篇牵头论文
  15. 冠心病Coronary heart disease10 篇牵头论文
  16. 先天性心脏病Congenital heart disease2 篇牵头论文
  17. 抗 NMDA 受体脑炎Anti-NMDA receptor encephalitis0 篇牵头论文
  18. 特发性肺纤维化Idiopathic pulmonary fibrosis1 篇牵头论文
  19. 法布雷病Fabry disease0 篇牵头论文
  20. 白塞病Behçet disease1 篇牵头论文
  21. Alport 综合征Alport syndrome1 篇牵头论文
  22. IgA 肾病IgA nephropathy0 篇牵头论文
  23. 原发性胆汁性胆管炎Primary biliary cholangitis0 篇牵头论文
  24. 遗传性血管性水肿Hereditary angioedema1 篇牵头论文

未列出的收录疾病:食管鳞状细胞癌、胶质瘤、肝母细胞瘤、脊索瘤、尤文肉瘤、多发性骨髓瘤、B 细胞急性淋巴细胞白血病、β 地中海贫血、血友病 A、非典型溶血性尿毒症综合征、范可尼贫血、视神经脊髓炎谱系疾病、IgG4相关性疾病、重症肌无力、烟雾病、肝豆状核变性、胆道闭锁、脊柱侧弯、大动脉炎、肝包虫病、肺淋巴管平滑肌瘤病、肌萎缩侧索硬化症、脊髓性肌萎缩症、庞贝病、杜氏肌营养不良、戈谢病、尼曼-匹克病 C 型、成骨不全症、原发性硬化性胆管炎、先天性膈疝、先天性巨结肠、遗传性大疱性表皮松解症、家族性腺瘤性息肉病、Leber 遗传性视神经病变、Majeed 综合征、NGLY1 缺乏症、ISG15 缺乏症。

癌症

鼻咽癌

Nasopharyngeal carcinoma

2021–2025 年中国大陆作者发表的 2,375 篇鼻咽癌 PubMed 英文论文中,这家医院牵头了 3 篇,占 0.1%。

牵头论文
3
2021–2025 年
牵头试验
0
任何状态,ClinicalTrials.gov
牵头的开放试验
0
正在或即将招募
作为研究中心的开放试验
0
由其他机构牵头
每年牵头的论文数
2021: 2220212022: 0020222023: 0020232024: 1120242025: 002025

烟台有 1 家医院列在鼻咽癌下全国有 183 家医院列在鼻咽癌下

截至 2026年11月8日,ClinicalTrials.gov 上没有列出这家医院的鼻咽癌开放试验。

这些数字背后的记录
研究主题放疗技术复发与转移
论文中的科室耳鼻喉/头颈外科放疗科

打开 PubMed 检索ClinicalTrials.gov

癌症

肝细胞癌

Hepatocellular carcinoma

2021–2025 年中国大陆作者发表的 14,765 篇肝细胞癌 PubMed 英文论文中,这家医院牵头了 12 篇,占 0.08%。

牵头论文
12
2021–2025 年
牵头试验
1
任何状态,ClinicalTrials.gov
牵头的开放试验
0
正在或即将招募
作为研究中心的开放试验
0
由其他机构牵头
每年牵头的论文数
2021: 1120212022: 3320222023: 2220232024: 5520242025: 112025

烟台有 1 家医院列在肝细胞癌下全国有 194 家医院列在肝细胞癌下

截至 2026年11月8日,ClinicalTrials.gov 上没有列出这家医院的肝细胞癌开放试验。

这些数字背后的记录
研究主题局部治疗(消融、TACE、HAIC)影像、人工智能与早期发现免疫与靶向药物
论文中的科室肿瘤内科普外/肝胆胰外科影像/核医学科消化/肝病科

这些论文过半是实验室或动物研究。

牵头的论文12
  1. Construction of a prognostic model and identification of key genes in liver hepatocellular carcinoma based on multi-omics data.2025Scientific reports免费全文
  2. Diagnostic efficacy of contrast-enhanced ultrasound, dynamic contrast-enhanced MRI combined with tumor markers AFP and DCP for primary hepatocellular carcinoma.2024Biotechnology & genetic engineering reviews
  3. hsa_circ_0072309 Inhibits Oncogenesis in Hepatocellular Carcinoma by Epigenetic Activation of its Host Gene.2024Cell biochemistry and biophysics
  4. Meta-Analysis on the Therapeutic Effect of Transcatheter Arterial Chemoembolization Combined with Portal Vein Embolization.2024Chemotherapy
  5. Sarcopenia as a prognostic factor in patients with hepatocellular carcinoma treated with transcatheter arterial chemoembolization plus sorafenib.2024Journal of cancer research and therapeutics
  6. Cost-Effectiveness Analysis of Hepatic Arterial Chemotherapy for Advanced Hepatocellular Carcinoma in China: A Comparative Analysis of HAIC-FO and Sorafenib.2024Medical science monitor : international medical journal of experimental and clinical research免费全文
  7. In vivo study revealed pro-tumorigenic effect of CMTM3 in hepatocellular carcinoma involving the regulation of peroxisome proliferator-activated receptor gamma (PPARγ).2023Cellular oncology (Dordrecht, Netherlands)免费全文
  8. Construction of pain prediction model for patients undergoing hepatic arterial chemoembolization.2023World journal of surgical oncology免费全文
  9. Circ_0005397 enhances hepatocellular carcinoma progression through miR-1283/HEG1.2022Annals of hepatology
  10. LINC00536 promotes hepatocellular carcinoma progression via the miR-203b-5p/VEGFA axis.2022Neoplasma
  11. Cell division cycle associated 2 (CDCA2) upregulation promotes the progression of hepatocellular carcinoma in a p53-dependant manner.2022PeerJ免费全文
  12. Long non-coding RNA 01559 mediates the malignant phenotypes of hepatocellular carcinoma cells through targeting miR-511.2021Clinics and research in hepatology and gastroenterology
它在 ClinicalTrials.gov 上的全部试验(任何状态)2
  1. Predictive Model for Pain After TACE已完成NCT05545046牵头方2019-09 启动
  2. TACE Combinated With Sorafenib in Treating Patients With Unresectable Hepatocellular Carcinoma状态不明NCT01605734研究中心II期2012-07 启动

打开 PubMed 检索ClinicalTrials.gov

癌症

胃癌

Stomach cancer

2021–2025 年中国大陆作者发表的 9,782 篇胃癌 PubMed 英文论文中,这家医院牵头了 33 篇,占 0.3%。

牵头论文
33
2021–2025 年
牵头试验
0
任何状态,ClinicalTrials.gov
牵头的开放试验
0
正在或即将招募
作为研究中心的开放试验
4
由其他机构牵头
每年牵头的论文数
2021: 7720212022: 6620222023: 6620232024: 5520242025: 992025

烟台有 1 家医院列在胃癌下全国有 211 家医院列在胃癌下

这家医院参与的开放试验 4

依据 ClinicalTrials.gov 在 2026年11月8日 的登记,包括正在招募、即将招募和邀请入组。仅在中国临床试验注册中心(ChiCTR)登记的试验不在其中。能否参加由研究团队决定。

  1. 正在招募
    TEAS Timing for Gastrectomy Recovery (TEAS-TIME Trial)
    分期
    不分期
    开始
    2026-07
    发布
    登记号
    NCT07714980

    年龄 18 岁 至 80 岁(登记的条件)

    牵头:青岛大学附属医院;另有 5 家列出的医院为研究中心北京、威海、潍坊、烟台、青岛

  2. 正在招募
    First-line Treatment With RC48 Plus Sintilimab and S-1 in Advanced Gastric Cancer (RCTS2)
    分期
    II期
    开始
    2024-10
    发布
    登记号
    NCT06730373

    年龄 18 岁 至 75 岁(登记的条件)

    牵头:山东大学齐鲁医院;另有 7 家列出的医院为研究中心临沂、济南、淄博、烟台、郑州、青岛

  3. 正在招募
    TEAS for Gastrectomy Recovery
    分期
    不分期
    开始
    2024-10
    发布
    登记号
    NCT07898293

    年龄 18 岁 至 80 岁(登记的条件)

    牵头:青岛大学附属医院;另有 2 家列出的医院为研究中心潍坊、烟台、青岛

  4. 正在招募
    A Phase 1/2a Study of DB-1303/BNT323 in Advanced/Metastatic Solid Tumors
    分期
    I/II期
    开始
    2022-01
    发布
    登记号
    NCT05150691

    年龄 18 岁 至 未注明(登记的条件)

    牵头方不是列出的医院;另有 34 家列出的医院为研究中心上海、北京、南宁、厦门、合肥、天津、安阳、广州、徐州、无锡、杭州、武汉、沈阳、济南、温州、烟台、石家庄、蚌埠、西安、郑州、重庆、长春、长沙

在试验总页面查看

排列:先正在招募,再即将招募和邀请入组;同类按开始时间从新到旧。不是排名。

这些数字背后的记录
研究主题免疫与靶向药物影像与人工智能手术
论文中的科室肿瘤内科消化/肝病科病理/检验科普外/肝胆胰外科
牵头的论文33
  1. Prognostic and immunological implications of protein kinases in gastric cancer: a focus on hub gene ABL2 and its impact on the polarization of M2 macrophages.2025Biology direct免费全文
  2. LRRC25 Is a Potential Biomarker for Predicting Immunotherapy Response in Patients with Gastric Cancer.2025Digestive diseases and sciences免费全文
  3. Real-World Efficacy of Cadonilimab Plus Chemotherapy as Second-Line Therapy in Immunotherapy-Pretreated Advanced HER2 Negative Gastric or Gastroesophageal Junction Cancer.2025Drug design, development and therapy免费全文
  4. Efficacy and safety of immunotherapy rechallenge in second-line treatment after failure of first-line immune checkpoint inhibitors combined with chemotherapy in advanced gastric cancer: a retrospective study.2025Frontiers in immunology免费全文
  5. Efficacy and safety of sintilimab combined with trastuzumab and chemotherapy in HER2-positive advanced gastric or gastroesophageal junction cancer.2025Frontiers in immunology免费全文
  6. Exploring Metabolomic Drivers of Colorectal and Gastric Cancer: A Mendelian Randomisation Study.2025Journal of the College of Physicians and Surgeons--Pakistan : JCPSP
  7. Macrophages in tertiary lymphoid structures promote apoptosis of ATF4-positive gastric cancer cells via IL18.2025Journal of translational medicine免费全文
  8. High glycemic variability serves as an independent risk factor for postoperative infection-related complications in patients undergoing radical surgery for gastric, colon, and rectal cancer.2025Medicine免费全文
  9. Cancer-associated fibroblast subtype and risk signature as predictors of prognosis and treatment effectiveness in gastric cancer.2025Scientific reports免费全文
  10. Effect of Intensive Nursing Management on Quality of Life and Mental Health in Elderly Gastric Cancer Patients Undergoing Chemotherapy: A Retrospective Study.2024British journal of hospital medicine (London, England : 2005)
  11. Case report: Significant response of alpha-fetoprotein-producing gastric cancer from combined chemotherapy and immunotherapy.2024Frontiers in immunology免费全文
  12. IGFL2 expression and surgical volume: Independent predictors of survival in gastric cancer.2024Medicine免费全文
  13. A disulfidptosis-related classification and risk signature identifies immunotherapy biomarkers and predicts prognosis in gastric cancer: An observational study.2024Medicine免费全文
  14. Construction and validation of a TTN mutation associated immune prognostic model for evaluating immune microenvironment and outcomes of gastric cancer: An observational study.2024Medicine免费全文
  15. Clinical characteristics and survival outcomes in patients with primary ovarian carcinoid: A historical cohort study.2023Acta obstetricia et gynecologica Scandinavica免费全文
  16. Gastric cystica profunda with upper GI bleeding.2023Asian journal of surgery
  17. LncRNA SNHG22 promotes gastric cancer progression by regulating the miR-101-3p/e2f2 axis.2023Cell cycle (Georgetown, Tex.)免费全文
  18. Circ-0000979 promotes the development of gastric carcinoma by sponging miR-136 and modulating SP1 mRNA expression level.2023Histology and histopathology
  19. TAF15 promotes cell proliferation, migration and invasion of gastric cancer via activation of the RAF1/MEK/ERK signalling pathway.2023Scientific reports免费全文
  20. SAMD4A serves as a negative prognostic marker for gastric cancer patients.2023Tissue & cell
  21. A new way of laparoscopic spleen-preserving splenic hilar lymphadenectomy for the treatment of upper gastric cancer.2022Asian journal of surgery
  22. LINC01857 promotes the proliferation, migration, and invasion of gastric cancer cells via regulating miR-4731-5p/HOXC6.2022Canadian journal of physiology and pharmacology
  23. Linc-ROR promotes invasion and metastasis of gastric cancer by activating epithelial-mesenchymal transition.2022Indian journal of pathology & microbiology
  24. Application of clinical nursing pathway in nursing care of patients undergoing gastric cancer surgery.2022Minerva gastroenterology
  25. Efficacy of the Short-Term versus Long-Term Administration of Antimicrobial Prophylaxis in Gastric Cancer Surgery: A Meta-Analysis of Randomized Controlled Trials.2022Surgical infections
  26. Complete remission of alpha-fetoprotein-producing gastric cancer by combined tislelizumab-apatinib treatment of a patient with proficient mismatch repair: a case report.2022World journal of surgical oncology免费全文
  27. EPLIN Expression in Gastric Cancer and Impact on Prognosis and Chemoresistance.2021Biomolecules免费全文
  28. DEPDC1 upregulation promotes cell proliferation and predicts poor prognosis in patients with gastric cancer.2021Cancer biomarkers : section A of Disease markers免费全文
  29. HIF1A-AS2 Promotes the Proliferation and Metastasis of Gastric Cancer Cells Through miR-429/PD-L1 Axis.2021Digestive diseases and sciences
  30. Diagnostic value of multi-slice spiral CT (MSCT) combined with digestive tract angiography in gastric fundus cardia carcinoma.2021Journal of B.U.ON. : official journal of the Balkan Union of Oncology
  31. LINC01232 Promotes Gastric Cancer Proliferation through Interacting with EZH2 to Inhibit the Transcription of KLF2.2021Journal of microbiology and biotechnology免费全文
  32. HOXB13 promotes gastric cancer cell migration and invasion via IGF-1R upregulation and subsequent activation of PI3K/AKT/mTOR signaling pathway.2021Life sciences
  33. Centromere Protein I (CENP-I) Is Upregulated in Gastric Cancer, Predicts Poor Prognosis, and Promotes Tumor Cell Proliferation and Migration.2021Technology in cancer research & treatment免费全文
它在 ClinicalTrials.gov 上的全部试验(任何状态)12
  1. TEAS Timing for Gastrectomy Recovery (TEAS-TIME Trial)正在招募NCT07714980研究中心不分期2026-07 启动
  2. TEAS for Gastrectomy Recovery正在招募NCT07898293研究中心不分期2024-10 启动
  3. First-line Treatment With RC48 Plus Sintilimab and S-1 in Advanced Gastric Cancer (RCTS2)正在招募NCT06730373研究中心II期2024-10 启动
  4. A Phase 1/2a Study of DB-1303/BNT323 in Advanced/Metastatic Solid Tumors正在招募NCT05150691研究中心I/II期2022-01 启动
  5. Postoperative Adjuvant Therapy for Stage II-III Gastric Cancer进行中,不再招募NCT06609759研究中心2024-01 启动
  6. Camrelizumab Combined With or Without Apatinib and SOX of Neoadjuvant Treatment for Gastric Cancer进行中,不再招募NCT06693128研究中心II期2024-11 启动
  7. Minimal Residual Disease-guided Adjuvant Therapy for Gastric Cancer进行中,不再招募NCT06157216研究中心不分期2023-10 启动
  8. First-line Treatment with RC48 Plus Tislelizumab and S-1(RCTS) in Advanced Gastric Cancer进行中,不再招募NCT05586061研究中心II期2023-02 启动
  9. Second-line Treatment With Serplulimab, Lenvatinib, and Paclitaxel in Advanced Gastric Cancer After Prior Immunotherapy进行中,不再招募NCT05585580研究中心II期2023-03 启动
  10. A Study of RC48-ADC in Local Advanced or Metastatic Gastric Cancer With the HER2-Overexpression状态不明NCT04714190研究中心III期2021-03 启动
  11. HX008 Plus Irinotecan Versus Placebo Plus Irinotecan as Second-line Treatment in Advanced Gastric Cancer状态不明NCT04486651研究中心III期2020-09 启动
  12. Perioperative Treatment of Combined SOX With Apatinib and Camrelizumab for Oesophagogastric Cancer进行中,不再招募NCT04208347研究中心II/III期2019-12 启动

打开 PubMed 检索ClinicalTrials.gov

癌症

肺癌

Lung cancer

2021–2025 年中国大陆作者发表的 23,356 篇肺癌 PubMed 英文论文中,这家医院牵头了 47 篇,占 0.2%。

牵头论文
47
2021–2025 年
牵头试验
1
任何状态,ClinicalTrials.gov
牵头的开放试验
1
正在或即将招募
作为研究中心的开放试验
4
由其他机构牵头
每年牵头的论文数
2021: 101020212022: 4420222023: 6620232024: 121220242025: 13132025

烟台有 2 家医院列在肺癌下全国有 251 家医院列在肺癌下

这家医院参与的开放试验 5

依据 ClinicalTrials.gov 在 2026年11月18日 的登记,包括正在招募、即将招募和邀请入组。仅在中国临床试验注册中心(ChiCTR)登记的试验不在其中。能否参加由研究团队决定。

  1. 正在招募
    A Phase II Study of Tislelizumab Plus Anlotinib Consolidation After Chemoradiotherapy in LS-SCLC
    分期
    II期
    开始
    2025-11
    发布
    登记号
    NCT07815223

    年龄 18 岁 至 75 岁(登记的条件)

    牵头:烟台毓璜顶医院烟台

  2. 正在招募
    A Study of Ifinatamab Deruxtecan Versus Treatment of Physician's Choice in Subjects With Relapsed Small Cell Lung Cancer
    分期
    III期
    开始
    2024-05
    发布
    登记号
    NCT06203210

    年龄 18 岁 至 未注明(登记的条件)

    牵头方不是列出的医院;另有 23 家列出的医院为研究中心上海、临沂、乌鲁木齐、北京、南昌、哈尔滨、天津、成都、杭州、武汉、沈阳、济南、烟台、襄阳、郑州、重庆、长沙

  3. 正在招募
    A Study of Amivantamab in Participants With Advanced or Metastatic Solid Tumors Including Epidermal Growth Factor Receptor (EGFR)-Mutated Non-Small Cell Lung Cancer
    分期
    II期
    开始
    2022-11
    发布
    登记号
    NCT05498428

    年龄 18 岁 至 未注明(登记的条件)

    牵头方不是列出的医院;另有 13 家列出的医院为研究中心上海、哈尔滨、天津、广州、成都、杭州、武汉、温州、烟台、石家庄、西安

  4. 正在招募
    Study of MCLA-129, a Human Bispecific EGFR and cMet Antibody, in Patients With Advanced NSCLC and Other Solid Tumors
    分期
    I/II期
    开始
    2021-09
    发布
    登记号
    NCT04930432

    年龄 18 岁 至 未注明(登记的条件)

    牵头方不是列出的医院;另有 56 家列出的医院为研究中心上海、兰州、北京、南京、南宁、南昌、南通、厦门、台州、合肥、哈尔滨、大连、天津、太原、广州、徐州、成都、昆明、杭州、武汉、汕头、沈阳、济南、深圳、温州、潍坊、烟台、石家庄、福州、苏州、蚌埠、西安、郑州、重庆、长春、长沙、青岛

  5. 即将招募
    A Prospective, Multicenter Exploratory Clinical Study on Consolidation Therapy With Tislelizumab Combined With Nintedanib for Limited-stage Small Cell Lung Cancer
    分期
    IV期
    开始
    2026-05
    发布
    登记号
    NCT07485920

    年龄 18 岁 至 未注明(登记的条件)

    牵头:青岛大学附属医院;另有 1 家列出的医院为研究中心烟台、青岛

在试验总页面查看

排列:先正在招募,再即将招募和邀请入组;同类按开始时间从新到旧。不是排名。

这些数字背后的记录
论文中的科室放疗科肿瘤内科病理/检验科耳鼻喉/头颈外科
牵头的论文47
  1. Deep learning-based classification of lung adenocarcinoma subtypes in histopathological images using DS-EffNet.2026Human pathology
  2. Clinical Characteristics and Diagnostic-Therapeutic Analysis of Pulmonary Benign Metastasizing Leiomyoma: A 10-Case Retrospective Study and Systematic Review.2026The American surgeon
  3. Single-Port Thoracoscopic Surgery via Areola Approach for Lung Cancer: Feasibility, Safety, and Initial Experience With a Novel Technique.2025ANZ journal of surgery
  4. Kartagener Syndrome Complicated by Middle and Lower Lobar Mucinous Adenocarcinoma in the Left Lung.2025Annals of thoracic and cardiovascular surgery : official journal of the Association of Thoracic and Cardiovascular Surgeons of Asia免费全文
  5. Cost-effectiveness analysis of penpulimab combined with paclitaxel and carboplatin as a first-line treatment for metastatic squamous non-small cell lung cancer in China.2025BMJ openRCT免费全文
  6. Clinical significance and biological function of PRKCQ-AS1/miR-582-3p expression in LUAD.2025Hereditas免费全文
  7. Four-gene Prognostic Signature and Risk of Brain Metastasis of Lung Adenocarcinoma.2025Molecular carcinogenesis免费全文
  8. Non-small cell lung cancer subtype classification based on cross-scale multi-instance learning.2025Scientific reports免费全文
  9. Advanced lung cancer inflammation index is associated with mortality in critically ill patients with non-traumatic cerebral hemorrhage.2025Scientific reports免费全文
  10. Cost-effectiveness of benmelstobart and anlotinib plus chemotherapy as first-line therapy for extensive-stage small cell lung cancer in China.2025Scientific reports免费全文
  11. The effect of oral nutritional supplementation combined with probiotics on the liver function and intestinal microflora in lung cancer chemotherapy patients through the gut-liver axis.2025Scientific reportsRCT免费全文
  12. Anlotinib as Maintenance Therapy After First-Line Chemotherapy Combined with Consolidation Radiation for Extensive-Stage Small Cell Lung Cancer.2025Technology in cancer research & treatment免费全文
  13. Effects of magnesium concentration on the regulation of nutrition and inflammation in nutritional support for cancer patients.2025The oncologist免费全文
  14. One-Stage Bilateral Pulmonary Nodule Resection via Unilateral Thoracic Cavity Access: A Single-Center Experience of 12 Cases.2025Thoracic cancer免费全文
  15. IMUP promotes fatty acid metabolism and lung cancer progression by regulating TGF-β/SMAD3 signaling pathway.2025Tissue & cell
  16. Surgery of enlarging lesions after stereotactic radiosurgery for brain metastases in patients with non-small cell lung cancer with oncogenic driver mutations frequently reveals radiation necrosis: case series and review.2024APMIS : acta pathologica, microbiologica, et immunologica Scandinavica
  17. Renal Metastasis Arising From a Pulmonary Adenoid Cystic Carcinoma: A Rare Case Report and Literature Review.2024American journal of men's health免费全文
  18. Sex-based immune microenvironmental feature heterogeneity in response to PD-1 blockade in combination with chemotherapy for patients with untreated advanced non-small-cell lung cancer.2024Cancer medicine免费全文
  19. Obese Mouse Fat Cell-derived Extracellular Vesicles Transport miR-99a-5p to Mitigate the Proliferation and Migration of Non-small Cell Lung Cancer Cells.2024Combinatorial chemistry & high throughput screening
  20. Inhaled delivery of cetuximab-conjugated immunoliposomes loaded with afatinib: A promising strategy for enhanced non-small cell lung cancer treatment.2024Drug delivery and translational research
  21. Incidence of thromboembolic events in non-small cell lung cancer patients treated with immune checkpoint inhibitors: A systematic review and meta-analysis.2024Journal of cancer research and therapeutics
  22. Prognostic significance of Pleural Fluid triglyceride levels based on a low-Fat Diet Management Strategy in patients with Chylothorax following pulmonary resection.2024Journal of cardiothoracic surgery免费全文
  23. S-(N,N-diethyldithiocarbamoyl)-N-acetyl-l-cysteine for the treatment of non-small cell lung cancer through regulating NF-κB signalling pathway without neurotoxicity.2024Journal of drug targeting
  24. A cisplatin and disulphiram co-loaded inclusion complex overcomes drug resistance by inhibiting cancer cell stemness in non-small cell lung cancer.2024Journal of drug targeting
  25. Prophylactic Cranial Irradiation in Limited-Stage Small Cell Lung Cancer: A Meta-Analysis.2024Journal of the College of Physicians and Surgeons--Pakistan : JCPSP
  26. A disulfiram derivative against lung cancer via the Notch signaling pathway without neurotoxicity and hepatotoxicity.2024Naunyn-Schmiedeberg's archives of pharmacology
  27. Integrated single-cell and bulk RNA-Seq analysis enhances prognostic accuracy of PD-1/PD-L1 immunotherapy response in lung adenocarcinoma through necroptotic anoikis gene signatures.2024Scientific reports免费全文
  28. Analysis and Validation of the Prognosis ability of the M7GRelated miRNAs in Lung Adenocarcinoma.2023Asian Pacific journal of cancer prevention : APJCP免费全文
  29. Tumor to liver maximum standardized uptake value ratio of FDG-PET/CT parameters predicts tumor treatment response and survival of stage III non-small cell lung cancer.2023BMC medical imaging免费全文
  30. The efficacy and safety of immune checkpoint inhibitors for patients with EGFR-mutated non-small cell lung cancer who progressed on EGFR tyrosine-kinase inhibitor therapy: A systematic review and network meta-analysis.2023Cancer medicine免费全文
  31. Tumour-pleura relationship on CT is a risk factor for occult lymph node metastasis in peripheral clinical stage IA solid adenocarcinoma.2023European radiology
  32. Clinical characteristics and establishment of a 2-year-OS predictive model of EGFR mutation-positive patients with pleural invasion of lung adenocarcinoma.2023Medicine免费全文
  33. m6A methylation reader IGF2BP2 activates endothelial cells to promote angiogenesis and metastasis of lung adenocarcinoma.2023Molecular cancer免费全文
  34. Development of six immune-related lncRNA signature prognostic model for smoking-positive lung adenocarcinoma.2022Journal of clinical laboratory analysis免费全文
  35. Mechanism of mPEGS and FGF2 in miR-574-5p regulating pemetrexed resistance of lung adenocarcinoma in nude mice.2022Minerva medica
  36. Effect and mechanism of mir-574-5p regulating mpegs on drug resistance of pC9/h1993 cells.2022Panminerva medica
  37. The Perspectives and Lived Experience of Postoperative Patients with Lung Cancer Participating in a Home-Based Exercise Intervention.2022Seminars in oncology nursing
  38. Combined prognostic value of the SUVmax derived from FDG-PET and the lymphocyte-monocyte ratio in patients with stage IIIB-IV non-small cell lung cancer receiving chemotherapy.2021BMC cancer免费全文
  39. Pinocembrin suppresses proliferation and enhances apoptosis in lung cancer cells in vitro by restraining autophagy.2021Bioengineered免费全文
  40. CircPRKCI regulates proliferation, migration and cycle of lung adenocarcinoma cells by targeting miR-219a-5p-regulated CAMK1D.2021European review for medical and pharmacological sciences
  41. Long non-coding RNA CCAT1 promotes non-small cell lung cancer progression by regulating the miR-216a-5p/RAP2B axis.2021Experimental biology and medicine (Maywood, N.J.)免费全文
  42. TWIST2 inhibits EMT and induces oxidative stress in lung cancer cells by regulating the FGF21-mediated AMPK/mTOR pathway.2021Experimental cell research
  43. Dosimetric Factors and Radiomics Features Within Different Regions of Interest in Planning CT Images for Improving the Prediction of Radiation Pneumonitis.2021International journal of radiation oncology, biology, physics
  44. CLK2 promotes occurrence and development of non-small cell lung cancer.2021Journal of B.U.ON. : official journal of the Balkan Union of Oncology
  45. FGF21 promotes non-small cell lung cancer progression by SIRT1/PI3K/AKT signaling.2021Life sciences
  46. Euphorbia angustifolia lactone B inhibits A549 proliferation and induces apoptosis.2021Pakistan journal of pharmaceutical sciences
  47. Pathological cytomorphologic features and the percentage of ALK FISH-positive cells predict pulmonary adenocarcinoma prognosis: a prospective cohort study.2021World journal of surgical oncology免费全文
中文论文(未计入)2
  1. [Pulmonary myopericytoma: report of a case].2025Zhonghua bing li xue za zhi = Chinese journal of pathology
  2. [A case report of alveolar adenoma].2025Zhonghua jie he he hu xi za zhi = Zhonghua jiehe he huxi zazhi = Chinese journal of tuberculosis and respiratory diseases
它在 ClinicalTrials.gov 上的全部试验(任何状态)22
  1. A Phase II Study of Tislelizumab Plus Anlotinib Consolidation After Chemoradiotherapy in LS-SCLC正在招募NCT07815223牵头方II期2025-11 启动
  2. A Prospective, Multicenter Exploratory Clinical Study on Consolidation Therapy With Tislelizumab Combined With Nintedanib for Limited-stage Small Cell Lung Cancer即将招募NCT07485920研究中心IV期2026-05 启动
  3. A Study of Ifinatamab Deruxtecan Versus Treatment of Physician's Choice in Subjects With Relapsed Small Cell Lung Cancer正在招募NCT06203210研究中心III期2024-05 启动
  4. A Study of Amivantamab in Participants With Advanced or Metastatic Solid Tumors Including Epidermal Growth Factor Receptor (EGFR)-Mutated Non-Small Cell Lung Cancer正在招募NCT05498428研究中心II期2022-11 启动
  5. Study of MCLA-129, a Human Bispecific EGFR and cMet Antibody, in Patients With Advanced NSCLC and Other Solid Tumors正在招募NCT04930432研究中心I/II期2021-09 启动
  6. A Study of Amivantamab and Capmatinib Combination Therapy in Unresectable Metastatic Non-small Cell Lung Cancer进行中,不再招募NCT05488314研究中心I/II期2022-12 启动
  7. A Study of DZD9008 Versus Platinum-Based Doublet Chemotherapy in Local Advanced or Metastatic Non-small Cell Lung Cancer (WU-KONG28)进行中,不再招募NCT05668988研究中心III期2022-12 启动
  8. Study of KN046 in Subjects With Advanced Non-Small Cell Lung Cancer已完成NCT05420220研究中心II期2022-07 启动
  9. A Study of Lazertinib With Subcutaneous Amivantamab Compared With Intravenous Amivantamab in Participants With Epidermal Growth Factor Receptor (EGFR)-Mutated Advanced or Metastatic Non-small Cell Lung Cancer进行中,不再招募NCT05388669研究中心III期2022-08 启动
  10. Phase II Study Investigating the Combination of Encorafenib and Binimetinib in BRAF V600E Mutated Chinese Patients With Metastatic Non-Small Cell Lung Cancer进行中,不再招募NCT05195632研究中心II期2022-06 启动
  11. Study of Ociperlimab Plus Tislelizumab Plus Chemoradiotherapy in Participants With Untreated Limited-Stage Small Cell Lung Cancer已完成NCT04952597研究中心II期2021-07 启动
  12. A Study of Amivantamab and Lazertinib in Combination With Platinum-Based Chemotherapy Compared With Platinum-Based Chemotherapy in Patients With Epidermal Growth Factor Receptor (EGFR)-Mutated Locally Advanced or Metastatic Non- Small Cell Lung Cancer After Osimertinib Failure进行中,不再招募NCT04988295研究中心III期2021-11 启动
  13. A Study of Ociperlimab With Tislelizumab Compared to Pembrolizumab in Participants With Untreated Lung Cancer已终止NCT04746924研究中心III期2021-05 启动
  14. A Study of Combination Amivantamab and Carboplatin-Pemetrexed Therapy, Compared With Carboplatin-Pemetrexed, in Participants With Advanced or Metastatic Non-Small Cell Lung Cancer Characterized by Epidermal Growth Factor Receptor (EGFR) Exon 20 Insertions进行中,不再招募NCT04538664研究中心III期2020-10 启动
  15. A Study of Amivantamab and Lazertinib Combination Therapy Versus Osimertinib in Locally Advanced or Metastatic Non-Small Cell Lung Cancer进行中,不再招募NCT04487080研究中心III期2020-09 启动
  16. Study of Platinum Plus Etoposide With or Without Tislelizumab in Participants With Untreated Extensive-Stage Small Cell Lung Cancer已完成NCT04005716研究中心III期2019-07 启动
  17. A Study Evaluates the Safety and Efficacy of WX-0593 in ALK -Positive, or ROS1-positive Non-small Cell Lung Cancer状态不明NCT04641754研究中心II期2019-03 启动
  18. Microwave Ablation in Combination With Camrelizumab Versus Camrelizumab in Metastatic Non-small-cell Lung Cancer状态不明NCT04102982研究中心II期2019-11 启动
  19. Microwave Ablation in Ground Glass Nodules状态不明NCT03490890研究中心II期2018-05 启动
  20. Docetaxel + Plinabulin Compared to Docetaxel + Placebo in Patients With Advanced NSCLC已完成NCT02504489研究中心III期2015-12 启动
  21. Individualized Adaptive Radiotherapy Based on PET/CT and IMRT for Locally Advanced Non-Small Cell Lung Cancer (NSCLC)状态不明NCT02790190研究中心III期2015-05 启动
  22. Microwave Plus Chemotherapy Versus Chemotherapy for Advanced NSCLC状态不明NCT02455843研究中心III期2015-05 启动

打开 PubMed 检索ClinicalTrials.gov

癌症

胰腺癌

Pancreatic cancer

2021–2025 年中国大陆作者发表的 5,743 篇胰腺癌 PubMed 英文论文中,这家医院牵头了 7 篇,占 0.1%。

牵头论文
7
2021–2025 年
牵头试验
0
任何状态,ClinicalTrials.gov
牵头的开放试验
0
正在或即将招募
作为研究中心的开放试验
0
由其他机构牵头
每年牵头的论文数
2021: 4420212022: 2220222023: 1120232024: 0020242025: 002025

烟台有 1 家医院列在胰腺癌下全国有 192 家医院列在胰腺癌下

截至 2026年11月18日,ClinicalTrials.gov 上没有列出这家医院的胰腺癌开放试验。

这些数字背后的记录
论文中的科室消化/肝病科影像/核医学科肿瘤内科

打开 PubMed 检索ClinicalTrials.gov

癌症

乳腺癌

Breast cancer

2021–2025 年中国大陆作者发表的 16,974 篇乳腺癌 PubMed 英文论文中,这家医院牵头了 45 篇,占 0.3%。

牵头论文
45
2021–2025 年
牵头试验
2
任何状态,ClinicalTrials.gov
牵头的开放试验
1
正在或即将招募
作为研究中心的开放试验
3
由其他机构牵头
每年牵头的论文数
2021: 9920212022: 3320222023: 101020232024: 131320242025: 992025

烟台有 1 家医院列在乳腺癌下全国有 219 家医院列在乳腺癌下

这家医院参与的开放试验 4

依据 ClinicalTrials.gov 在 2026年11月18日 的登记,包括正在招募、即将招募和邀请入组。仅在中国临床试验注册中心(ChiCTR)登记的试验不在其中。能否参加由研究团队决定。

  1. 即将招募
    A Prospective, Single-center, Phase II Study of Sacituzumab Tirumotecan in Combination With Pembrolizumab for Neoadjuvant Treatment of Triple-Negative Breast Cancer (TNBC)
    分期
    II期
    开始
    2025-10
    发布
    登记号
    NCT07054242

    年龄 18 岁 至 75 岁(登记的条件)

    牵头:烟台毓璜顶医院烟台

  2. 正在招募
    Real-world Study of SKB264 Monotherapy or Combination Therapy in Recurrent or Metastatic HER2-negative Breast Cancer
    分期
    未注明
    开始
    2026-05
    发布
    登记号
    NCT06993506

    年龄 18 岁 至 未注明(登记的条件)

    牵头:中国医学科学院肿瘤医院;另有 12 家列出的医院为研究中心上海、北京、厦门、合肥、武汉、烟台、石家庄、福州、郑州、长春

  3. 正在招募
    A Clinical Study of Neoadjuvant Treatment With TQB2102 for Injection for Human Epidermal Growth Factor Receptor 2 (HER2) Positive Breast Cancer
    分期
    III期
    开始
    2025-09
    发布
    登记号
    NCT07043725

    年龄 18 岁 至 75 岁(登记的条件)

    牵头方不是列出的医院;另有 52 家列出的医院为研究中心上海、临沂、乌鲁木齐、兰州、北京、南京、南宁、南昌、台州、合肥、哈尔滨、天津、太原、宁波、安阳、广州、成都、新乡、梅州、武汉、汕头、沈阳、泉州、泸州、洛阳、济南、温州、潍坊、烟台、石家庄、蚌埠、衡阳、西安、贵阳、郑州、重庆、长春、长沙

  4. 正在招募
    A Trial Comparing GQ1005 and T-DM1 in Patients With HER2-Positive Unresectable or Metastatic Breast Cancer
    分期
    III期
    开始
    2025-01
    发布
    登记号
    NCT07673029

    年龄 18 岁 至 75 岁(登记的条件)

    牵头方不是列出的医院;另有 51 家列出的医院为研究中心上海、临沂、北京、南宁、南昌、合肥、哈尔滨、大连、天津、太原、安阳、广州、徐州、成都、新乡、昆明、杭州、梅州、武汉、汕头、沈阳、泉州、洛阳、济南、潍坊、烟台、石家庄、福州、蚌埠、西安、贵阳、郑州、重庆、长春、长沙、青岛

在试验总页面查看

排列:先正在招募,再即将招募和邀请入组;同类按开始时间从新到旧。不是排名。

这些数字背后的记录
论文中的科室影像/核医学科肿瘤内科病理/检验科放疗科
牵头的论文45
  1. Prediction of non-sentinel lymph node metastasis using the clinical features of thrombin time under the status of 1-2 positive sentinel lymph node of breast cancer.2026Future oncology (London, England)免费全文
  2. Exosome Platform with Three-in-One Functionality of mRNA Therapy, Immune Checkpoint Blockade, and Mild Photothermal Therapy for the Treatment of Triple-Negative Breast Cancer.2025ACS applied materials & interfaces
  3. Predicting axillary lymph node metastasis in breast cancer patients using CNN-GCN on DCE-MRI: a multicenter study.2025BMC medical imaging免费全文
  4. Piezo1-mediated cellular apoptosis in breast cancer cells triggered by ultrasound and microbubbles.2025Cellular and molecular biology (Noisy-le-Grand, France)
  5. Anlotinib or Bevacizumab Combined with Taxane/Capecitabine for the Second-Line or Subsequent Treatment of HER-2 Negative Metastatic Breast Cancer: A Retrospective Cohort Study.2025Drug design, development and therapy免费全文
  6. Comparative Analysis of Clinical Efficacy and Safety of Pyrotinib Plus Capecitabine versus Trastuzumab Emtansine (T-DM1) as Second-Line Treatment for HER2-Positive Advanced Breast Cancer: A Retrospective Study.2025Drug design, development and therapy免费全文
  7. Development and multicenter external validation of an intratumoral and peritumoral ultrasound-based radiomics model for preoperative prediction of HER2 status in IHC 2 + breast cancer.2025European journal of medical research免费全文
  8. Development and Validation of a Deep Learning System to Differentiate HER2-Zero, HER2-Low, and HER2-Positive Breast Cancer Based on Dynamic Contrast-Enhanced MRI.2025Journal of magnetic resonance imaging : JMRI
  9. Application of TRPS1 in ER-negative or low expression distant metastatic breast carcinoma.2025Pathology oncology research : POR免费全文
  10. Cyclophilin J inhibited oxidative stress and apoptosis in triple-negative breast cancer cell through activating the PI3K/Akt signaling pathway.2025Toxicology and applied pharmacology
  11. Develop and Validate a Nomogram Combining Contrast-Enhanced Spectral Mammography Deep Learning with Clinical-Pathological Features to Predict Neoadjuvant Chemotherapy Response in Patients with ER-Positive/HER2-Negative Breast Cancer.2024Academic radiology
  12. FAM110A could serve as a prognostic biomarker for patients with breast cancer: A comprehensive analysis by integrating bulk and single-cell sequencing.2024Asian journal of surgery
  13. Neuroendocrine Neoplasms of the Breast: Current Insights and Future Directions.2024Cancer reports (Hoboken, N.J.)免费全文
  14. A Case Report of Invasive Lobular Carcinoma of Breast with Multiple Gastrointestinal and Cutaneous Metastases.2024Current medical imaging
  15. Intracranial Efficacy of Pyrotinib and Capecitabine Combination Therapy in HER2-Positive Breast Cancer with Brain Metastases.2024Drug design, development and therapy免费全文
  16. Multiregional dynamic contrast-enhanced MRI-based integrated system for predicting pathological complete response of axillary lymph node to neoadjuvant chemotherapy in breast cancer: multicentre study.2024EBioMedicine免费全文
  17. Role of contrast-enhanced mammography in the preoperative detection of ductal carcinoma in situ of the breasts: a comparison with low-energy image and magnetic resonance imaging.2024European radiology
  18. Extrachromosomal circular DNA landscape of breast cancer with lymph node metastasis.2024International journal of cancer
  19. Artificial intelligence-based classification of breast lesion from contrast enhanced mammography: a multicenter study.2024International journal of surgery (London, England)免费全文
  20. Multitask Deep Learning-Based Whole-Process System for Automatic Diagnosis of Breast Lesions and Axillary Lymph Node Metastasis Discrimination from Dynamic Contrast-Enhanced-MRI: A Multicenter Study.2024Journal of magnetic resonance imaging : JMRI
  21. Nuclei detection in breast histopathology images with iterative correction.2024Medical & biological engineering & computing
  22. Low-intensity pulsed ultrasound combined with microbubble mediated JNK/c-Jun pathway to reverse multidrug resistance in triple-negative breast cancer.2024Scientific reports免费全文
  23. Mammographically detected breast clustered microcalcifications localized by chest thin-section computed tomography.2024World journal of surgical oncology免费全文
  24. Intra- and Peritumoral Radiomics of Contrast-Enhanced Mammography Predicts Axillary Lymph Node Metastasis in Patients With Breast Cancer: A Multicenter Study.2023Academic radiology
  25. Attention-based deep learning for breast lesions classification on contrast enhanced spectral mammography: a multicentre study.2023British journal of cancer免费全文
  26. Homologous recombination deficiency prediction using low-pass whole genome sequencing in breast cancer.2023Cancer genetics
  27. Landscape of NcRNAs involved in drug resistance of breast cancer.2023Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico免费全文
  28. Prognostic value of left ventricular global longitudinal strain on speckle echocardiography for predicting chemotherapy-induced cardiotoxicity in breast cancer patients: A systematic review and meta-analysis.2023Echocardiography (Mount Kisco, N.Y.)
  29. Single nucleotide polymorphisms associated with female breast cancer susceptibility in Chinese population.2023Gene
  30. Radiomics of contrast-enhanced spectral mammography for prediction of pathological complete response to neoadjuvant chemotherapy in breast cancer.2023Journal of X-ray science and technology免费全文
  31. Attention-based Deep Learning for the Preoperative Differentiation of Axillary Lymph Node Metastasis in Breast Cancer on DCE-MRI.2023Journal of magnetic resonance imaging : JMRI
  32. Qualitative assessments of density and background parenchymal enhancement on contrast-enhanced spectral mammography associated with breast cancer risk in high-risk women.2023The British journal of radiology免费全文
  33. Intratumoral and peritumoral radiomics for preoperatively predicting the axillary non-sentinel lymph node metastasis in breast cancer on the basis of contrast-enhanced mammography: a multicenter study.2023The British journal of radiology免费全文
  34. miR-146a Enhances the Sensitivity of Breast Cancer Cells to Paclitaxel by Downregulating IRAK1.2022Cancer biotherapy & radiopharmaceuticals
  35. Intratumoral and peritumoral radiomics for preoperative prediction of neoadjuvant chemotherapy effect in breast cancer based on contrast-enhanced spectral mammography.2022European radiology
  36. Validation of absolutely quantitated Ki67 and cyclinD1 protein levels for prognosis of Luminal-like breast cancer patients.2022Journal of clinical laboratory analysis免费全文
  37. Identification of candidate biomarkers correlated with poor prognosis of breast cancer based on bioinformatics analysis.2021Bioengineered免费全文
  38. The correlation of 18F-FDG PET/CT metabolic parameters, clinicopathological factors, and prognosis in breast cancer.2021Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico
  39. Radiomic analysis on magnetic resonance diffusion weighted image in distinguishing triple-negative breast cancer from other subtypes: a feasibility study.2021Clinical imaging
  40. Multiview multimodal network for breast cancer diagnosis in contrast-enhanced spectral mammography images.2021International journal of computer assisted radiology and surgery
  41. MIR31HG regulates the proliferation, migration and invasion of breast cancer by regulating the expression of POLDIP2.2021Journal of B.U.ON. : official journal of the Balkan Union of Oncology
  42. Preoperative prediction of histologic grade in invasive breast cancer by using contrast-enhanced spectral mammography-based radiomics.2021Journal of X-ray science and technology
  43. ELK1-induced up-regulation of KIF26B promotes cell cycle progression in breast cancer.2021Medical oncology (Northwood, London, England)
  44. Quantitative analysis of contrast enhanced spectral mammography grey value for early prediction of pathological response of breast cancer to neoadjuvant chemotherapy.2021Scientific reports免费全文
  45. Mammography-based radiomics for predicting the risk of breast cancer recurrence: a multicenter study.2021The British journal of radiology免费全文
中文论文(未计入)1
  1. [The value of immunohistochemical expression of Ki-67 and CD34 in differentiating ductal carcinoma in situ from ductal carcinoma in situ-like invasive breast cancer].2022Zhonghua bing li xue za zhi = Chinese journal of pathology
它在 ClinicalTrials.gov 上的全部试验(任何状态)10
  1. A Prospective, Single-center, Phase II Study of Sacituzumab Tirumotecan in Combination With Pembrolizumab for Neoadjuvant Treatment of Triple-Negative Breast Cancer (TNBC)即将招募NCT07054242牵头方II期2025-10 启动
  2. Pyrotinib Combined With Trastuzumab,Dalpiciclib and Letrozole for HR+/HER2+ Breast Cancer状态不明NCT05800756牵头方II期2022-08 启动
  3. Real-world Study of SKB264 Monotherapy or Combination Therapy in Recurrent or Metastatic HER2-negative Breast Cancer正在招募NCT06993506研究中心2026-05 启动
  4. A Clinical Study of Neoadjuvant Treatment With TQB2102 for Injection for Human Epidermal Growth Factor Receptor 2 (HER2) Positive Breast Cancer正在招募NCT07043725研究中心III期2025-09 启动
  5. A Trial Comparing GQ1005 and T-DM1 in Patients With HER2-Positive Unresectable or Metastatic Breast Cancer正在招募NCT07673029研究中心III期2025-01 启动
  6. A Study to Evaluate the Efficacy and Safety of HLX11 vs. EU-Perjeta® in the Neoadjuvant Therapy of HER2-Positive and HR-Negative Early-stage or Locally Advanced Breast Cancer进行中,不再招募NCT05346224研究中心III期2022-04 启动
  7. GB491 Combined With Fulvestrant for HR+ HER2- Locally Advanced or Metastatic Breast Cancer已完成NCT05054751研究中心III期2021-09 启动
  8. A Study of RC48-ADC Administered Intravenously to Patients With HER2-Positive Metastatic Breast Cancer With or Without Liver Metastases状态不明NCT03500380研究中心II/III期2018-04 启动
  9. Compare Efficacy, Safety and Immunogenicity of HLX02 and Herceptin in Previously Untreated HER2 +Overexpressing Metastatic Breast Cancer已完成NCT03084237研究中心III期2016-11 启动
  10. Aromasin® Interventional Study Of Early Invasive Breast Cancer Patients In China已完成NCT01176916研究中心IV期2011-02 启动

打开 PubMed 检索ClinicalTrials.gov

癌症

视网膜母细胞瘤

Retinoblastoma

2021–2025 年中国大陆作者发表的 301 篇视网膜母细胞瘤 PubMed 英文论文中,这家医院牵头了 2 篇,占 0.7%。

牵头论文
2
2021–2025 年
牵头试验
0
任何状态,ClinicalTrials.gov
牵头的开放试验
0
正在或即将招募
作为研究中心的开放试验
0
由其他机构牵头
每年牵头的论文数
2021: 1120212022: 0020222023: 0020232024: 0020242025: 112025

烟台有 3 家医院列在视网膜母细胞瘤下全国有 176 家医院列在视网膜母细胞瘤下

截至 2026年11月13日,ClinicalTrials.gov 上没有列出这家医院的视网膜母细胞瘤开放试验。

这些数字背后的记录
论文中的科室眼科/神经眼科

打开 PubMed 检索ClinicalTrials.gov

癌症

骨肉瘤

Osteosarcoma

2021–2025 年中国大陆作者发表的 2,257 篇骨肉瘤 PubMed 英文论文中,这家医院牵头了 3 篇,占 0.1%。

牵头论文
3
2021–2025 年
牵头试验
0
任何状态,ClinicalTrials.gov
牵头的开放试验
0
正在或即将招募
作为研究中心的开放试验
0
由其他机构牵头
每年牵头的论文数
2021: 0020212022: 0020222023: 0020232024: 1120242025: 112025

烟台有 8 家医院列在骨肉瘤下全国有 570 家医院列在骨肉瘤下

截至 2026年11月13日,ClinicalTrials.gov 上没有列出这家医院的骨肉瘤开放试验。

这些数字背后的记录
论文中的科室放疗科

打开 PubMed 检索ClinicalTrials.gov

癌症

胃肠道间质瘤

Gastrointestinal stromal tumour

2021–2025 年中国大陆作者发表的 523 篇胃肠道间质瘤 PubMed 英文论文中,这家医院牵头了 2 篇,占 0.4%。

牵头论文
2
2021–2025 年
牵头试验
0
任何状态,ClinicalTrials.gov
牵头的开放试验
0
正在或即将招募
作为研究中心的开放试验
0
由其他机构牵头
每年牵头的论文数
2021: 0020212022: 0020222023: 1120232024: 1120242025: 002025

烟台有 3 家医院列在胃肠道间质瘤下全国有 240 家医院列在胃肠道间质瘤下

截至 2026年11月13日,ClinicalTrials.gov 上没有列出这家医院的胃肠道间质瘤开放试验。

这些数字背后的记录
论文中的科室消化/肝病科

打开 PubMed 检索ClinicalTrials.gov

癌症

神经母细胞瘤

Neuroblastoma

2021–2025 年中国大陆作者发表的 1,132 篇神经母细胞瘤 PubMed 英文论文中,这家医院牵头了 1 篇,占 0.09%。

牵头论文
1
2021–2025 年
牵头试验
0
任何状态,ClinicalTrials.gov
牵头的开放试验
0
正在或即将招募
作为研究中心的开放试验
0
由其他机构牵头
每年牵头的论文数
2021: 0020212022: 0020222023: 1120232024: 0020242025: 002025

烟台有 4 家医院列在神经母细胞瘤下全国有 321 家医院列在神经母细胞瘤下

截至 2026年11月13日,ClinicalTrials.gov 上没有列出这家医院的神经母细胞瘤开放试验。

这些数字背后的记录
论文中的科室病理/检验科神经内科

打开 PubMed 检索ClinicalTrials.gov

血液疾病

再生障碍性贫血

Aplastic anaemia

2021–2025 年中国大陆作者发表的 412 篇再生障碍性贫血 PubMed 英文论文中,这家医院牵头了 1 篇,占 0.2%。

牵头论文
1
2021–2025 年
牵头试验
0
任何状态,ClinicalTrials.gov
牵头的开放试验
0
正在或即将招募
作为研究中心的开放试验
0
由其他机构牵头
每年牵头的论文数
2021: 0020212022: 1120222023: 0020232024: 0020242025: 002025

烟台有 2 家医院列在再生障碍性贫血下全国有 63 家医院列在再生障碍性贫血下

截至 2026年11月8日,ClinicalTrials.gov 上没有列出这家医院的再生障碍性贫血开放试验。

这些数字背后的记录
研究主题感染与支持治疗

打开 PubMed 检索ClinicalTrials.gov

血液疾病

噬血细胞性淋巴组织细胞增生症

Haemophagocytic lymphohistiocytosis

2021–2025 年中国大陆作者发表的 399 篇噬血细胞性淋巴组织细胞增生症 PubMed 英文论文中,这家医院牵头了 1 篇,占 0.2%。

牵头论文
1
2021–2025 年
牵头试验
0
任何状态,ClinicalTrials.gov
牵头的开放试验
0
正在或即将招募
作为研究中心的开放试验
0
由其他机构牵头
每年牵头的论文数
2021: 0020212022: 1120222023: 0020232024: 0020242025: 002025

烟台有 1 家医院列在噬血细胞性淋巴组织细胞增生症下全国有 66 家医院列在噬血细胞性淋巴组织细胞增生症下

截至 2026年11月8日,ClinicalTrials.gov 上没有列出这家医院的噬血细胞性淋巴组织细胞增生症开放试验。

这些数字背后的记录
研究主题治疗方案EB病毒与感染诱因淋巴瘤及肿瘤相关噬血
论文中的科室耳鼻喉/头颈外科
牵头的论文1
  1. Successful treatment of hemophagocytic syndrome in a patient with T cell lymphoma, EBV infection, and bone marrow necrosis: A case report.2022Medicine免费全文
中文论文(未计入)1
  1. [Successful treatment of hemophagocytic syndrome caused by auricle infection: one case report].2021Zhonghua er bi yan hou tou jing wai ke za zhi = Chinese journal of otorhinolaryngology head and neck surgery

打开 PubMed 检索ClinicalTrials.gov

血液疾病

淋巴瘤

Lymphoma

2021–2025 年中国大陆作者发表的 3,830 篇淋巴瘤 PubMed 英文论文中,这家医院牵头了 12 篇,占 0.3%。

牵头论文
12
2021–2025 年
牵头试验
0
任何状态,ClinicalTrials.gov
牵头的开放试验
0
正在或即将招募
作为研究中心的开放试验
5
由其他机构牵头
每年牵头的论文数
2021: 1120212022: 2220222023: 3320232024: 2220242025: 332025

烟台有 1 家医院列在淋巴瘤下全国有 199 家医院列在淋巴瘤下

这家医院参与的开放试验 5

依据 ClinicalTrials.gov 在 2026年11月18日 的登记,包括正在招募、即将招募和邀请入组。仅在中国临床试验注册中心(ChiCTR)登记的试验不在其中。能否参加由研究团队决定。

  1. 正在招募
    An Engineered Sirpα Fused to Anti-Pd-L1 And Tgf-β Fusion Protein (HCB301) in Subjects With Selected Advanced Tumors
    分期
    I期
    开始
    2025-04
    发布
    登记号
    NCT06487624

    年龄 18 岁 至 未注明(登记的条件)

    牵头方不是列出的医院;另有 3 家列出的医院为研究中心广州、杭州、烟台

  2. 正在招募
    Clinical Trial of TQB2825 Injection Combined Immunochemotherapy in Subjects With Diffuse Large B Cell Lymphoma
    分期
    I/II期
    开始
    2025-04
    发布
    登记号
    NCT06829771

    年龄 18 岁 至 80 岁(登记的条件)

    牵头方不是列出的医院;另有 17 家列出的医院为研究中心上海、兰州、北京、哈尔滨、天津、太原、广州、徐州、武汉、泉州、泸州、烟台、福州、蚌埠、西安、郑州、长春

  3. 正在招募
    An Observational Study of Glofitamab in Chinese Adult Participants With 2L Diffuse Large B-Cell Lymphoma
    分期
    未注明
    开始
    2025-09
    发布
    登记号
    NCT07200375

    年龄 18 岁 至 未注明(登记的条件)

    牵头方不是列出的医院;另有 18 家列出的医院为研究中心上海、北京、南昌、哈尔滨、天津、宁波、广州、成都、武汉、济南、温州、烟台、西安、郑州、长春

  4. 正在招募
    Efficacy and Safety of Orelabrutinib Combined With Rituximab Versus Lenalidomide Combined With Rituximab in Patients With Relapsed/Refractory Marginal Zone Lymphoma
    分期
    III期
    开始
    2023-12
    发布
    登记号
    NCT06082102

    年龄 18 岁 至 未注明(登记的条件)

    牵头方不是列出的医院;另有 18 家列出的医院为研究中心上海、北京、南昌、大连、广州、成都、杭州、武汉、沈阳、烟台、蚌埠、西安、郑州、长沙、青岛

  5. 即将招募
    Evaluation of the Efficacy and Safety of TQB2825 Injection Compared to Immunotherapy in the Treatment of Recurrent/Refractory Follicular Lymphoma
    分期
    III期
    开始
    2025-11
    发布
    登记号
    NCT07187960

    年龄 18 岁 至 80 岁(登记的条件)

    牵头方不是列出的医院;另有 19 家列出的医院为研究中心上海、临沂、兰州、北京、南京、南昌、天津、太原、武汉、沈阳、海口、烟台、西安、贵阳、郑州、重庆

在试验总页面查看

排列:先正在招募,再即将招募和邀请入组;同类按开始时间从新到旧。不是排名。

这些数字背后的记录
论文中的科室病理/检验科影像/核医学科耳鼻喉/头颈外科
牵头的论文12
  1. Diagnostic challenges and considerations in CD30-negative classical Hodgkin lymphoma from biopsy specimens.2026Annals of diagnostic pathology
  2. Genetic alterations and their prognostic impact in marginal zone lymphoma: a meta-analysis.2025Annals of hematology免费全文
  3. Clinical analysis of lymphoma with malignant solid tumor simultaneously: a retrospective case series.2025Diagnostic pathology免费全文
  4. Case Report: Epstein-Barr virus-positive follicular lymphoma with high PD-L1 expression.2025Frontiers in immunology免费全文
  5. Clinical significance of Cyclin D1 by complete quantification detection in mantle cell lymphoma: positive indicator in prognosis.2024Diagnostic pathology免费全文
  6. Nodal T follicular helper cell lymphoma with aberrant CD20 expression and monoclonal TCR, IG rearrangements secondary to Classical Hodgkin Lymphoma: a case report.2024Medical molecular morphology
  7. Advanced Ann Arbor stage and age over 60 years as prognostic predictors in patients with primary cervical lymphoma: a retrospective cohort study and systematic review.2023BMC cancer免费全文
  8. An extranodal Richter's syndrome presenting with cardiac diffuse large B-cell lymphoma: a case report.2023BMC cardiovascular disorders免费全文
  9. Differentiation between atypical sinonasal non-Hodgkin's lymphoma and inverted papilloma.2023Clinical radiology
  10. Targeting MYC and BCL2 by a natural compound for "double-hit" lymphoma.2022Hematological oncology免费全文
  11. Successful treatment of hemophagocytic syndrome in a patient with T cell lymphoma, EBV infection, and bone marrow necrosis: A case report.2022Medicine免费全文
  12. Differentiating Glioblastoma from Primary Central Nervous System Lymphoma: The Value of Shaping and Nonenhancing Peritumoral Hyperintense Gyral Lesion on FLAIR Imaging.2021World neurosurgery
中文论文(未计入)3
  1. [Diffuse large B cell lymphoma misdiagnosed as peritonsillar abscess: a case report].2022Zhonghua er bi yan hou tou jing wai ke za zhi = Chinese journal of otorhinolaryngology head and neck surgery
  2. [Safety and the short-term efficacy of bendamustine in the conditioning regimen for autologous stem cell transplantation in patients with lymphoma].2022Zhonghua xue ye xue za zhi = Zhonghua xueyexue zazhi免费全文
  3. [Primary small lymphocytic lymphoma/chronic lymphocytic leukemia of the appendix with acute appendicitis as the first symptom: report of a case].2021Zhonghua bing li xue za zhi = Chinese journal of pathology
它在 ClinicalTrials.gov 上的全部试验(任何状态)7
  1. An Engineered Sirpα Fused to Anti-Pd-L1 And Tgf-β Fusion Protein (HCB301) in Subjects With Selected Advanced Tumors正在招募NCT06487624研究中心I期2025-04 启动
  2. Evaluation of the Efficacy and Safety of TQB2825 Injection Compared to Immunotherapy in the Treatment of Recurrent/Refractory Follicular Lymphoma即将招募NCT07187960研究中心III期2025-11 启动
  3. An Observational Study of Glofitamab in Chinese Adult Participants With 2L Diffuse Large B-Cell Lymphoma正在招募NCT07200375研究中心2025-09 启动
  4. Clinical Trial of TQB2825 Injection Combined Immunochemotherapy in Subjects With Diffuse Large B Cell Lymphoma正在招募NCT06829771研究中心I/II期2025-04 启动
  5. Efficacy and Safety of Orelabrutinib Combined With Rituximab Versus Lenalidomide Combined With Rituximab in Patients With Relapsed/Refractory Marginal Zone Lymphoma正在招募NCT06082102研究中心III期2023-12 启动
  6. A Sub-study Trial of Epcoritamab vs Investigator's Choice Chemotherapy in Relapsed/Refractory Diffuse Large B-cell Lymphoma (R/R DLBCL) in China进行中,不再招募NCT07226752研究中心III期2022-10 启动
  7. Study of BGB-11417 in Participants With Relapsed or Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma进行中,不再招募NCT05479994研究中心II期2022-10 启动

打开 PubMed 检索ClinicalTrials.gov

血液疾病

血栓性血小板减少性紫癜

Thrombotic thrombocytopenic purpura

2021–2025 年中国大陆作者发表的 64 篇血栓性血小板减少性紫癜 PubMed 英文论文中,这家医院牵头了 1 篇,占 1.6%。

牵头论文
1
2021–2025 年
牵头试验
0
任何状态,ClinicalTrials.gov
牵头的开放试验
0
正在或即将招募
作为研究中心的开放试验
0
由其他机构牵头
每年牵头的论文数
2021: 0020212022: 0020222023: 1120232024: 0020242025: 002025

烟台有 1 家医院列在血栓性血小板减少性紫癜下全国有 59 家医院列在血栓性血小板减少性紫癜下

截至 2026年11月13日,ClinicalTrials.gov 上没有列出这家医院的血栓性血小板减少性紫癜开放试验。

这些数字背后的记录
牵头的论文1
  1. ADAMTS13 Biomarkers in Management of Immune Thrombotic Thrombocytopenic Purpura.2023Archives of pathology & laboratory medicine免费全文

打开 PubMed 检索ClinicalTrials.gov

其他疾病

冠心病

Coronary heart disease

2021–2025 年中国大陆作者发表的 5,119 篇冠心病 PubMed 英文论文中,这家医院牵头了 10 篇,占 0.2%。

牵头论文
10
2021–2025 年
牵头试验
0
任何状态,ClinicalTrials.gov
牵头的开放试验
0
正在或即将招募
作为研究中心的开放试验
2
由其他机构牵头
每年牵头的论文数
2021: 0020212022: 2220222023: 1120232024: 4420242025: 332025

烟台有 1 家医院列在冠心病下全国有 231 家医院列在冠心病下

这家医院参与的开放试验 2

依据 ClinicalTrials.gov 在 2026年11月18日 的登记,包括正在招募、即将招募和邀请入组。仅在中国临床试验注册中心(ChiCTR)登记的试验不在其中。能否参加由研究团队决定。

  1. 正在招募
    Efficacy and Safety Trials of Yangxinshi Tablets in the Treatment of Patients With Coronary Heart Disease Complicated by Cardiac Dysfunction
    分期
    IV期
    开始
    2025-11
    发布
    登记号
    NCT07110415

    年龄 40 岁 至 80 岁(登记的条件)

    牵头方不是列出的医院;另有 41 家列出的医院为研究中心上海、兰州、北京、南京、南宁、哈尔滨、大庆、大连、天津、宁波、广州、张家口、成都、杭州、汕头、沈阳、济南、深圳、湖州、烟台、珠海、石家庄、西安、贵阳、重庆、银川、长春、青岛

  2. 即将招募
    Optimized Antiplatelet Therapy in Patients With CHD After Implantation of NeoVas™ BRS System
    分期
    不分期
    开始
    2021-09
    发布
    登记号
    NCT04995159

    年龄 18 岁 至 未注明(登记的条件)

    牵头方不是列出的医院;另有 67 家列出的医院为研究中心上海、中山、兰州、北京、南京、南宁、南昌、合肥、哈尔滨、天津、太原、广州、徐州、昆明、杭州、武汉、汕头、洛阳、济南、海口、淄博、淮安、湛江、烟台、珠海、石家庄、蚌埠、西安、贵阳、郑州、重庆、银川、长春、长沙、青岛

在试验总页面查看

排列:先正在招募,再即将招募和邀请入组;同类按开始时间从新到旧。不是排名。

这些数字背后的记录
论文中的科室影像/核医学科神经内科
牵头的论文10
  1. Tumour necrosis factor alpha-inducing protein 3 (TNFAIP3) can independently predict coronary heart disease (CHD).2025Acta cardiologica
  2. Combining echocardiography with carotid ultrasound parameters in predicting major adverse cardiovascular events among older individuals with coronary artery disease.2025PeerJ免费全文
  3. Abnormal peripheral microcirculation by nailfold videocapillaroscopy reveals severity of atherosclerosis in coronary heart disease.2025Scientific reports免费全文
  4. The diagnostic value of echocardiography combined with serum Hcy and PCSK9 in coronary heart disease.2024Biotechnology & genetic engineering reviews
  5. Screening significance of systemic immune-inflammation index (SII) and systemic inflammation response index (SIRI) in coronary heart disease of symptomatic youth.2024Immunity, inflammation and disease免费全文
  6. Unlocking Cardioprotective Potential of Gut Microbiome: Exploring Therapeutic Strategies.2024Journal of microbiology and biotechnology免费全文
  7. Image testing based on biomedical drug loading in cardiovascular drug care simulation for coronary heart disease.2024Medical engineering & physics
  8. Decreased Regional Spontaneous Brain Activity and Cognitive Dysfunction in Patients with Coronary Heart Disease: a Resting-state Functional MRI Study.2023Academic radiology
  9. Association of early repolarization pattern and ventricular fibrillation in patients with vasospastic angina: A systematic review and meta-analysis.2022Clinical cardiology免费全文
  10. Effect of Mobile Internet on Attitude and Self-Efficacy of Patients with Coronary Heart Disease Diagnosed by 12-Lead Holter ECG.2022Journal of healthcare engineering免费全文
它在 ClinicalTrials.gov 上的全部试验(任何状态)3
  1. Efficacy and Safety Trials of Yangxinshi Tablets in the Treatment of Patients With Coronary Heart Disease Complicated by Cardiac Dysfunction正在招募NCT07110415研究中心IV期2025-11 启动
  2. Optimized Antiplatelet Therapy in Patients With CHD After Implantation of NeoVas™ BRS System即将招募NCT04995159研究中心不分期2021-09 启动
  3. A Trial to Evaluate Efficacy of Heart-protecting Musk Pill状态不明NCT01897805研究中心IV期2011-07 启动

打开 PubMed 检索ClinicalTrials.gov

其他疾病

先天性心脏病

Congenital heart disease

2021–2025 年中国大陆作者发表的 2,604 篇先天性心脏病 PubMed 英文论文中,这家医院牵头了 2 篇,占 0.08%。

牵头论文
2
2021–2025 年
牵头试验
0
任何状态,ClinicalTrials.gov
牵头的开放试验
0
正在或即将招募
作为研究中心的开放试验
0
由其他机构牵头
每年牵头的论文数
2021: 0020212022: 0020222023: 0020232024: 1120242025: 112025

烟台有 1 家医院列在先天性心脏病下全国有 207 家医院列在先天性心脏病下

截至 2026年11月18日,ClinicalTrials.gov 上没有列出这家医院的先天性心脏病开放试验。

这些数字背后的记录
论文中的科室神经外科
牵头的论文2
  1. Kartagener Syndrome Complicated by Middle and Lower Lobar Mucinous Adenocarcinoma in the Left Lung.2025Annals of thoracic and cardiovascular surgery : official journal of the Association of Thoracic and Cardiovascular Surgeons of Asia免费全文
  2. Subdural Empyema Associated with Ventricular Septal Defect.2024Neurology India
中文论文(未计入)1
  1. [A case of long QT syndrome with atypical clinical phenotype caused by KCNQ1-R555C missense mutation].2023Zhonghua xin xue guan bing za zhi

打开 PubMed 检索ClinicalTrials.gov

其他疾病

抗 NMDA 受体脑炎

Anti-NMDA receptor encephalitis

2021–2025 年没有牵头抗 NMDA 受体脑炎的 PubMed 英文论文。下方可查看与这家医院关联的研究记录。

牵头论文
0
2021–2025 年
牵头试验
0
任何状态,ClinicalTrials.gov
牵头的开放试验
0
正在或即将招募
作为研究中心的开放试验
0
由其他机构牵头

烟台有 1 家医院列在抗 NMDA 受体脑炎下全国有 124 家医院列在抗 NMDA 受体脑炎下

截至 2026年11月13日,ClinicalTrials.gov 上没有列出这家医院的抗 NMDA 受体脑炎开放试验。

这些数字背后的记录
早期论文(2016–2020 年)2
  1. Focus on autonomic dysfunctions in anti-NMDAR encephalitis: a case report.2019European review for medical and pharmacological sciences
  2. Teratoma-associated anti-NMDAR encephalitis: Two cases report and literature review.2017Medicine

打开 PubMed 检索ClinicalTrials.gov

其他疾病

特发性肺纤维化

Idiopathic pulmonary fibrosis

2021–2025 年中国大陆作者发表的 989 篇特发性肺纤维化 PubMed 英文论文中,这家医院牵头了 1 篇,占 0.1%。

牵头论文
1
2021–2025 年
牵头试验
0
任何状态,ClinicalTrials.gov
牵头的开放试验
0
正在或即将招募
作为研究中心的开放试验
0
由其他机构牵头
每年牵头的论文数
2021: 0020212022: 0020222023: 1120232024: 0020242025: 002025

烟台有 2 家医院列在特发性肺纤维化下全国有 288 家医院列在特发性肺纤维化下

截至 2026年11月13日,ClinicalTrials.gov 上没有列出这家医院的特发性肺纤维化开放试验。

这些数字背后的记录
论文中的科室风湿免疫科

打开 PubMed 检索ClinicalTrials.gov

其他疾病

法布雷病

Fabry disease

2021–2025 年没有牵头法布雷病的 PubMed 英文论文。下方可查看与这家医院关联的研究记录。

牵头论文
0
2021–2025 年
牵头试验
0
任何状态,ClinicalTrials.gov
牵头的开放试验
0
正在或即将招募
作为研究中心的开放试验
0
由其他机构牵头

烟台有 1 家医院列在法布雷病下全国有 80 家医院列在法布雷病下

截至 2026年11月13日,ClinicalTrials.gov 上没有列出这家医院的法布雷病开放试验。

这些数字背后的记录

打开 PubMed 检索ClinicalTrials.gov

其他疾病

白塞病

Behçet disease

2021–2025 年中国大陆作者发表的 245 篇白塞病 PubMed 英文论文中,这家医院牵头了 1 篇,占 0.4%。

牵头论文
1
2021–2025 年
牵头试验
0
任何状态,ClinicalTrials.gov
牵头的开放试验
0
正在或即将招募
作为研究中心的开放试验
0
由其他机构牵头
每年牵头的论文数
2021: 0020212022: 1120222023: 0020232024: 0020242025: 002025

烟台有 1 家医院列在白塞病下全国有 139 家医院列在白塞病下

截至 2026年11月13日,ClinicalTrials.gov 上没有列出这家医院的白塞病开放试验。

这些数字背后的记录
论文中的科室风湿免疫科

打开 PubMed 检索ClinicalTrials.gov

其他疾病

Alport 综合征

Alport syndrome

2021–2025 年中国大陆作者发表的 58 篇Alport 综合征 PubMed 英文论文中,这家医院牵头了 1 篇,占 1.7%。

牵头论文
1
2021–2025 年
牵头试验
0
任何状态,ClinicalTrials.gov
牵头的开放试验
0
正在或即将招募
作为研究中心的开放试验
0
由其他机构牵头
每年牵头的论文数
2021: 0020212022: 0020222023: 0020232024: 1120242025: 002025

烟台有 2 家医院列在Alport 综合征下全国有 60 家医院列在Alport 综合征下

截至 2026年11月13日,ClinicalTrials.gov 上没有列出这家医院的Alport 综合征开放试验。

这些数字背后的记录

打开 PubMed 检索ClinicalTrials.gov

其他疾病

IgA 肾病

IgA nephropathy

2021–2025 年没有牵头IgA 肾病的 PubMed 英文论文。下方可查看与这家医院关联的研究记录。

牵头论文
0
2021–2025 年
牵头试验
0
任何状态,ClinicalTrials.gov
牵头的开放试验
0
正在或即将招募
作为研究中心的开放试验
0
由其他机构牵头

烟台有 3 家医院列在IgA 肾病下全国有 300 家医院列在IgA 肾病下

截至 2026年11月13日,ClinicalTrials.gov 上没有列出这家医院的IgA 肾病开放试验。

这些数字背后的记录
它在 ClinicalTrials.gov 上的全部试验(任何状态)4
  1. A Clinical Study of SCTC21C in Participants With Plasma Cell-driven Autoimmune Diseases即将招募NCT06774664研究中心I/II期2025-01 启动
  2. A Study of Telitacicept for IgA Nephropathy (TELIGAN)进行中,不再招募NCT05799287研究中心III期2023-04 启动
  3. Efficacy and Safety of Abelmoschus Manihot for IgA Nephropathy状态不明NCT02231125研究中心IV期2014-09 启动
  4. Therapeutic Evaluation of Steroids in IgA Nephropathy Global Study (TESTING Low Dose Study)已完成NCT01560052研究中心不分期2012-05 启动

打开 PubMed 检索ClinicalTrials.gov

其他疾病

原发性胆汁性胆管炎

Primary biliary cholangitis

2021–2025 年没有牵头原发性胆汁性胆管炎的 PubMed 英文论文。下方可查看与这家医院关联的研究记录。

牵头论文
0
2021–2025 年
牵头试验
0
任何状态,ClinicalTrials.gov
牵头的开放试验
0
正在或即将招募
作为研究中心的开放试验
0
由其他机构牵头

烟台有 1 家医院列在原发性胆汁性胆管炎下全国有 153 家医院列在原发性胆汁性胆管炎下

截至 2026年11月13日,ClinicalTrials.gov 上没有列出这家医院的原发性胆汁性胆管炎开放试验。

这些数字背后的记录

打开 PubMed 检索ClinicalTrials.gov

其他疾病

遗传性血管性水肿

Hereditary angioedema

2021–2025 年中国大陆作者发表的 32 篇遗传性血管性水肿 PubMed 英文论文中,这家医院牵头了 1 篇,占 3.1%。

牵头论文
1
2021–2025 年
牵头试验
0
任何状态,ClinicalTrials.gov
牵头的开放试验
0
正在或即将招募
作为研究中心的开放试验
0
由其他机构牵头
每年牵头的论文数
2021: 0020212022: 0020222023: 0020232024: 0020242025: 112025

烟台有 1 家医院列在遗传性血管性水肿下全国有 30 家医院列在遗传性血管性水肿下

截至 2026年11月13日,ClinicalTrials.gov 上没有列出这家医院的遗传性血管性水肿开放试验。

这些数字背后的记录
论文中的科室耳鼻喉/头颈外科
牵头的论文1
  1. Hereditary angioedema-induced laryngeal edema: A diagnostic and therapeutic race against time.2025The American journal of emergency medicine
它在 ClinicalTrials.gov 上的全部试验(任何状态)2
  1. A Phase 2 in Adult Subjects With Hereditary Angioedema进行中,不再招募NCT06846398研究中心II期2025-02 启动
  2. A Study of Lanadelumab (SHP643) in Chinese Participants With Hereditary Angioedema (HAE)已完成NCT05460325研究中心III期2022-06 启动

打开 PubMed 检索ClinicalTrials.gov

联系这家医院

出示给工作人员或司机的院名卡

烟台毓璜顶医院

Yantai Yuhuangding Hospital

烟台

大医院往往有多个院区,出发前请先向医院确认院区。

中英对照的咨询信

填写方括号中的内容后,通过医院国际医疗部或官网上的联系方式发送。在这里输入的内容不会离开您的设备。

医院通常需要的资料

  • 主治医生近期的病情总结或信件
  • 病理报告
  • 影像检查(CT、MRI、PET)及报告,尽量附影像文件
  • 已接受的治疗及时间
  • 目前用药

下一步建议

与主治医生沟通可将本页分享给主治医生,一同评估该团队的研究方向是否相关。
确认团队现状论文发表通常滞后数月,医生也可能调动。请在医院官网查询相关科室。
直接联系医院请通过医院官方公布的渠道联系。医院不向我们支付任何费用;是否接诊由医院决定。

这些数字从哪里来

论文

2021–2025 年 PubMed 英文论文中,第一作者或最后作者的第一单位是这家医院的论文。 定义

试验

ClinicalTrials.gov 上列出这家医院为牵头方或研究中心的记录,截至 2026年11月8日。

编号与其他名称

ROR Wikidata
Affiliated Yantai Yuhuangding Hospital of Qingdao University; Yantai Yuhuangding Hospital Affiliated to Qingdao University; Yuhuangding Hospital; Yuhuangding Hospital of Yantai; Affiliated Yantai Yuhuangding Hospital; Yuhuangding Hospital Affiliated to Qingdao University; Yantai Yuhuangding Hospital of Qingdao University; Yantai Yuhuangding Hospital Affilliated to Qingdao University

提出更正下载数据